Medicinal products may only be distributed in Switzerland if they are authorised by Swissmedic. The Swiss Agency for Therapeutic Products, is involved in the entire life cycle of a medicinal products because of its mandated areas of responsibility in the sectors of licensing and the authorisation and monitoring of medicinal products.
Authorisations of human medicinal products with a new active substance and additional indications 2023
41 human medicinal products with new active substances authorised
Overview of new authorisations 2023
In 2023, Swissmedic, the Swiss Agency for Therapeutic Products, authorised 41 medicinal products with new active substances for the Swiss market.
The overview shows the indications and the type and duration of the authorisation procedures. Swissmedic is also participating in two benchmarking studies to compare the authorisation times with those of the leading partner authorities. The results of these studies will be published during the course of 2024.
The following overview shows which procedures the applicants used, how long the authorisation processes lasted, and for which indications the medicines were authorised.